Answers are grounded in this paper and cite their sources.
To describe the EMERGE (NCT05550207) trial; a phase 3 multi-center open-label trial evaluating the efficacy and safety of AXS-07 in the acute treatment of migraine headache in adults with a prior inadequate response to an oral calcitonin gene-related peptide (CGRP) inhibitor.
No takes yet. Share an insight, caveat, or question.
McAllister et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: